RxDoctor Payments Data

Ruma Sanyal, MD

Internal Medicine · Flushing, NYNPI 1760567960

Payments from drug & device makers

$781in general payments, 2019–2025

Across 38 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$292
  • Lilly USA, LLC$206
  • Amgen$78
  • Bayer$66
  • Astellas Pharma US Inc$62
  • Pfizer$46
  • plus $32 from 1 others

What the payments were for

  • Food & beverage$781100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca14$292
Lilly USA, LLC10$206
Amgen4$78
Bayer2$66
Astellas Pharma US Inc3$62
Pfizer3$46
Merck2$32

How this compares

$781 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$4,006
Medicare patients
11
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol67$60,685
JanuviaSitagliptin Phosphate41$32,052
JanumetSitagliptin Phos/Metformin Hcl30$25,367
OzempicSemaglutide24$21,848
JardianceEmpagliflozin13$19,170
Breo ElliptaFluticasone/Vilanterol18$11,073
ShingrixVaricella-Zoster Ge/As01b/Pf15$2,707
Albuterol Sulfate HfaAlbuterol Sulfate24$1,142
Losartan Potassium61$817
Levothyroxine Sodium40$602
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide27$600
Atorvastatin Calcium56$514
Calcitonin-SalmonCalcitonin,salmon,synthetic13$501
Famotidine64$500
Diclofenac Sodium48$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$292$60,68567 claims
MerckJanuvia, Janumet$32$57,41971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →